SCHEMBL15437474

SCHEMBL15437474

Cc1noc(-c2ccc(NS(C)(=O)=O)cc2)c1N(C(=O)O)[C@H](C)c1ccc(F)cc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.39
NR3C2 P08235 2/20 0.36
BRD4 O60885 1/20 0.35
MAP2K4 P45985 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
RORC P51449 2/20 0.35
RORA P35398 1/20 0.35
NR1H2 P55055 1/20 0.35
NR1H3 Q13133 1/20 0.35
RORB Q92753 1/20 0.35
TNIK Q9UKE5 1/20 0.34
NR3C1 P04150 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
SGK1 O00141 1/20 0.33
LPAR1 Q92633 1/20 0.33
LPAR2 Q9HBW0 1/20 0.33
LPAR3 Q9UBY5 1/20 0.33
SCN5A Q14524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15437876 1.00 SCN9A (0.39) SCN9ANR3C2BRD4MAP2K4ALDH1A1
SCHEMBL15437378 0.91 KIF11 (0.38) BRD4HPGDRORCRORANR1H2
SCHEMBL15437499 0.89 LPAR1 (0.42) NR3C2RORCRORANR1H2NR1H3
SCHEMBL15437826 0.89 LPAR1 (0.42) NR3C2RORCRORANR1H2NR1H3
SCHEMBL15438023 0.88 KIF11 (0.37) BRD4RORCRORANR1H2NR1H3
SCHEMBL15437361 0.84 RORC (0.38) NR3C2BRD4MAP2K4ALDH1A1RORC
SCHEMBL15437757 0.83 MAPT (0.36) SCN9ARORCRORANR1H2NR1H3
SCHEMBL15437669 0.82 KIF11 (0.43) BRD4RORCRORANR1H2NR1H3
SCHEMBL4032476 0.81 LPAR1 (0.43) ALDH1A1LPAR1LPAR2LPAR3FTO
SCHEMBL15437817 0.81 LPAR1 (0.41) ALDH1A1RORCRORANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785442-B2 Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof CUREGENIX, INC. (CN) 2014-07-22 US claimed
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF CUREGENIX, INC. (CN) 2014-01-30 US claimed
US-8785442-B2 Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof CUREGENIX, INC. (CN) 2014-07-22 US disclosed
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF CUREGENIX, INC. (CN) 2014-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031353-A1 COMPOUND AS ANTAGONIST OF LYSOPHOSPHATIDIC ACID RECEPTOR, COMPOSITION, AND USE THEREOF LPAR1, LPAR2, LPAR5 SCN9A 2398/4885NR3C2 919/4885BRD4 1846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.